Clinical Trials Logo

Huntington's Disease clinical trials

View clinical trials related to Huntington's Disease.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03225846 Terminated - Clinical trials for Huntington's Disease

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

PRECISION-HD2
Start date: July 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).

NCT ID: NCT03225833 Terminated - Clinical trials for Huntington's Disease

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

PRECISION-HD1
Start date: July 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120101 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362307 (SNP1).

NCT ID: NCT02494778 Terminated - Clinical trials for Huntington's Disease

A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

Open PRIDE-HD
Start date: September 24, 2015
Phase: Phase 2
Study type: Interventional

The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).

NCT ID: NCT02342548 Terminated - Clinical trials for Huntington's Disease

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Start date: February 25, 2015
Phase: Phase 2
Study type: Interventional

This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920. Secondary endpoints will be the change from baseline in the Total Motor Score (TMS)assessment, and/ior the Total maximum Chorea (TMC) assessment of the Unified Huntington Disease Rating Scale (UHDRS) after 6 and 12 months of treatment, and Clinical Global Impression-Improvement score after 6 and 12 months of treatment. Subjects, who were assigned to the 20 mg PF-02545920 dose group in the preceding A8241021 study, will receive 20 mg PF-02545920 without any titration. All other subjects will be titrated to the 20 mg BID dose as follows: 5 mg BID for 7 days, 10 mg BID for 7 days, 15 mg BID for 7 days, then 20 mg BID for the remainder of the treatment phase. Up to 260 subjects may take part in this open label extension

NCT ID: NCT02231580 Terminated - Clinical trials for Huntington's Disease

Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients

Start date: September 1, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease (HD).

NCT ID: NCT02074410 Terminated - Clinical trials for Huntington's Disease

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).

NCT ID: NCT01019473 Terminated - Clinical trials for Huntington's Disease

Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea

Start date: November 2009
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.

NCT ID: NCT00712426 Terminated - Clinical trials for Huntington's Disease

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

CREST-E
Start date: September 2009
Phase: Phase 3
Study type: Interventional

Huntington's disease (HD) is a slowly progressive disorder that devastates the lives of those affected and their families. There are no treatments that slow the progression of HD, only mildly effective symptomatic therapies are available.Creatine monohydrate is considered a nutritional supplement. The purpose of CREST-E is to test whether high-dose creatine can slow the progressive functional decline that occurs in persons 18 years or older with early clinical features of HD. The long-term safety, tolerability and effectiveness of up to 40 grams daily creatine compared to placebo is studied. A variety of biological processes are assessed for markers of disease activity or progression and creatine effects. Up to 50 active research centers globally will enroll 650 subjects.